



NEWS RELEASE

Repligen Corporation to Present at Upcoming Investor Conferences

2023-11-07

WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences.

- Stifel 2023 Healthcare Conference being held November 14-15 in New York City. Tony J. Hunt, Chief Executive Officer, will participate in an analyst-led discussion on Wednesday, November 15, at 8:00 a.m. ET.
- Stephens' Annual Investment Conference being held November 14-16 in Nashville. Tony J. Hunt, Chief Executive Officer, will participate in an analyst-led discussion on Thursday, November 16, at 11:00 a.m. ET.

A live webcast of the conference presentations will be accessible through Repligen's **Investor Relations** website at www.repligen.com, and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a life sciences tools and technology company that develops and markets highly innovative bioprocessing solutions and systems. Our products enable efficiencies in the process of manufacturing a wide range of biological drugs, including: monoclonal antibodies; recombinant proteins; cell and gene therapies; and vaccines. We are inspiring advances in bioprocessing for the customers we serve around the globe; primarily biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, see our website at www.repligen.com and follow us on **LinkedIn**.

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

investors@repligen.com

Source: Repligen Corporation